Here are the five functional stages of the device:

Stage 1: A one microliter sample, 50 times smaller than a tear drop, is pipetted onto the chip, where the capillary forces begin to take effect.

Stage 2: These forces push the sample through an intricate series of mesh structures, which prevent clogging and air bubbles from forming.

Stage 3: The sample then passes into a region where microscopically small amounts of the detection antibody have been deposited. These antibodies have a fluorescent tag and similar to the antibodies within our body, they recognize the disease marker and attach to it within the sample. Only seventy picoliters (a volume one million times smaller than a tear) of these antibodies are used, making their dissolution in the passing sample extremely fast and efficient.

Stage 4: The most critical stage is called the "reaction chamber" and it measures 30 micrometers in width and 20 micrometers in depth, roughly the diameter of a strand of human hair. Similar to a common pregnancy test, in this stage the disease marker that was previously tagged is captured on the surface of the chamber. By shining a focused beam of red light, the tagged disease markers can be viewed using a portable sensor device that contains a chip similar to those used by digital cameras, albeit this one being much more sensitive. Based on the amount of light detected, medical professionals can visually confirm the strength of the disease marker in the sample to determine the next course of treatment.

Stage 5: Less a stage and more a part of the entire process is the capillary pump. The capillary pump, which has a depth of 180 micrometers, contains an intricate set of microstructures, the job of which is to pump the sample through the device for as long as needed and at a regular flow rate, just like the human heart. This pump makes the test accurate, portable and simple to use. IBM scientists have developed a library of capillary pumps so that tests needing a variety of sample

More from IBM Research: IBM Scientists Reinvent Medical Diagnostic Testing ...

Abstract in Lab on a Chip: Toward one-step point-of-care immunodiagnostics using capillary-driven microfluidics and PDMS substrates

The Company's lead cancer treatment, OncoVEX^GM-CSF is a first-in-class oncolytic, or cancer destroying virus, that works by replicating and spreading within solid tumors (leaving healthy cells unaffected), thereby causing cancer cell death and stimulating the immune system to destroy un-injected metastatic deposits. Both modes of action have been clearly validated in the clinic, where multiple patients with metastatic disease progressing at enrollment have been declared disease free. BioVex believes OncoVEX^GM-CSF has the potential to become a leading standard of care in the treatment of many solid tumors based on the strength of clinical data so far generated coupled with the relatively benign side effect profile noted to date. Previous clinical trials have enrolled patients with breast cancer, melanoma, head and neck cancer and pancreatic cancer, with indications of clinical activity being observed in each.

Press releases: BIOVEX ANNOUNCES PUBLICATION OF PHASE 2 MELANOMA RESULTS WITH ONCOVEXGM-CSF IN THE JOURNAL OF CLINICAL ONCOLOGY...; BIOVEX COMPLETES $70 MILLION FINANCING TO CONCLUDE PIVOTAL STUDY WITH ITS PIONEERING CANCER TREATMENT, ONCOVEXGM-CSF...

Abstract in Journal of Clinical Oncology: Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor-Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma

Image: Transmission electron micrograph of 4 views of Herpes simplex virus, computer-coloured mauve. Wellcome Images.

Track your chemotherapy schedule, medication, and treatment plan

Record some of the possible side effects from chemotherapy treatments, such as nausea, vomiting, pain, fatigue, change in temperature, lack of appetite, tingling in feet or toes, diarrhea, constipation, and rash

Create reports that include chemotherapy, medications, and some of the possible side effects on a daily or weekly basis

Share your results and discuss your symptoms with your doctor or nurse so you can have a more accurate and informed discussion

Product page: iChemoDiary ...

The microsensors on the chip record, among other things, changes in the acid content of the medium and the cells’ oxygen consumption; photographs of the process are also taken by a microscope fitted underneath the microtitre plate. All of the data merge in a computer that is connected to the system, and which provides an overview of the metabolic activity of the tumor cells and their vitality.

The robots and microtitre plates are kept in a climatic chamber, which, through precisely regulated temperature and humidity, provides an environment similar to that of the human body, and also protects the tumor cells against external influences that can falsify the test results.

After the tumor cells have been able to divide undisturbed for a few hours, the robot applies an anti-cancer substance. If their metabolic activity declines over the next day or two, the active substance was able to kill the tumor cells and the drug is effective. Using the microchips, twenty-four active substances or combinations of active substances can be tested simultaneously in this way.

The gain in time for the patient is not the only positive factor here. Dr. Helmut Grothe, a scientist from the Heinz Nixdorf Chair at the TUM, explains: “Treatment with an ineffective cancer drug sometimes leads to the development of resistance to other drugs in the patient.” Such resistance on the part of the tumor cells can also be identified at an early stage with the help of the sensor chip.

Another advantage of the system is its automation. The robot works faster and more accurately than any human could. Hence, the test results can be obtained quickly, which, in turn, saves on costs. Furthermore, the possibility of testing tumor cells with several active substances simultaneously facilitates the search for effective substances for individually-tailored cancer treatment. Pharmaceutical companies may also be able to use the sensor chip in the development of new drugs in future.

As part of another research project, the scientists at the Heinz Nixdorf Chair are also developing a sensor chip that is intended to control tumor growth. The chip, which would be implanted once in the vicinity of the tumor, could release cancer drugs or pain medication only when the tumor grows. The release of the active substances would be controlled by electric impulses. This sensor system could be used in the treatment of inoperable tumors, for example pancreatic tumors.

Full story from Technische Universität München: Mini-Lab for Cancer Diagnosis....

From The Engineer Online:

While the concept behind their techniques is relatively the same, the materials used to make the bubbles differ. The Transave bubble is based on a lipid and the Strathclyde University team has developed a bubble made of a surfactant, cholesterol and dicetylphosphate.

Katharine Carter, a member of the Strathclyde University research team, said the reagents that make up their bubble are more robust, and the manufacturing method has the potential to be much simpler.

Neither technique is commercially available; however, Transave has already taken its drug-delivery system to stage two clinical trials, while Strathclyde is still performing animal testing.

The technique would work by placing drug-containing bubbles in the solution container of a nebuliser. Carter said their animal trials indicate a patient would only have to breathe in the bubbles for 6.5 minutes.

When the bubbles reach the lung, she added, they will be met by a vast amount of macrophages, which are white blood cells that break down pathogens with special enzymes.

Carter explained that these macrophages would recognise the bubbles as a pathogen and bust them open. 'The drug will then be released locally at the cells and into the environment nearby,' she said.

More from The Engineer Online...

TRANSAVE: Proprietary Liposomal Technology

University of Strathclyde: Novel Chemotherapy Targeting System based on Nanoparticles...

>Dr. Kelly's work demonstrates that the cells can be differentiated with these biomarkers because of the cellular genes that indicate aggressive or benign forms. The scanning electron micrograph illustrates the eight variable structures that the system can repeatably track with less than 5% variation. Analysis time is reported to be 30 minutes as compared with contemporary diagnostics tests which can take days.

The researchers' new device can easily sense the signature biomarkers that indicate the presence of cancer at the cellular level, even though these biomolecules - genes that indicate aggressive or benign forms of the disease and differentiate subtypes of the cancer - are generally present only at low levels in biological samples. Analysis can be completed in 30 minutes, a vast improvement over the existing diagnostic procedures that generally take days.

"Today, it takes a room filled with computers to evaluate a clinically relevant sample of cancer biomarkers and the results aren't quickly available," said Shana Kelley, a professor in the Leslie Dan Faculty of Pharmacy and the Faculty of Medicine, who was a lead investigator on the project and a co-author on the publication.

"Our team was able to measure biomolecules on an electronic chip the size of your fingertip and analyse the sample within half an hour. The instrumentation required for this analysis can be contained within a unit the size of a BlackBerry."

Press release: U of T researchers create microchip that can detect type and severity of cancer...

Nature: Programming nucleic acids detection sensitivity using controlled nanostructuring

University of Toronto: Shana Kelly Lab

(hat tip: Next Big Future)

With cows' livers standing in for human tissue and 10mm and 5mm blobs of glue wrapped in wire representing tumours, the researchers compared palpation by surgeons, non-surgeons and the robot in the blinded trials. The researchers used a torque sensor to measure the force of the palpations.

Using tactile MIS sensing instruments under robotic control reduces the maximum force applied to the tissue by over 35% compared to a human controlling the same instrument. Accuracy in detecting the tumours was also far greater with the robot - between 59 and 90% depending on the robot control method used for palpation.

Unlike humans, the robot applies consistent force in each step, and moves over the tissue systematically. This produces a complete map, equivalent to one large pad applying ideal levels of force to the whole sample. (Similar to tactile sensors that have been developed to detect breast tumours.)

Humans do not know from one palpation to the next exactly how much force they are applying. This means some features are only highlighted because the surgeon is applying more force, or because the human user has changed the angle slightly between the instrument and the tissue. It is also easier to miss a tumour due to applying slightly lower force.

In fact both surgeons and non-surgeons were more likely to cause tissue damage than the robot. When a subject observed increased pressure on the visual display, they tended to focus on the area and apply even more force to see if what they had observed was a tumour. In the case of MIS, only a very small area can be palpated, which makes it challenging to compare adjacent areas and search for a tumour manually.

Press release: Robot's gentle touch aids delicate cancer surgery ...

Article in The International Journal of Robotics Research: Robot-assisted Tactile Sensing for Minimally Invasive Tumor Localization

More details from the product page:

The IsoFlow catheter enables sideways perfusion, which gives you the ability to push specified fluids both into side branch and angiogenicly formed vessels, letting medications reach an isolated area in a highly targeted and concentrated fashion. With IsoFlow's unique design, fluids can reach areas that could not previously be treated directly.

IsoFlow is inserted with a guide wire and catheter for precise positioning within a patient's body. Once in place, both of IsoFlow's balloons are simultaneously inflated using radiopaque fluid via a single inflation lumen. Physician-specified fluid is introduced through the infusion lumen or the guide wire lumen via the one-way stopcock connection. The mixture of infusion and radiopaque agents is then delivered to the target region between the two balloons. For sideways infusion, the guide wire is retracted to allow blood to bypass the isolated target region via holes in the catheter exterior. Complete removal of the guide wire allows fluid delivery from the distal tip.

Watch the video for how the IsoFlow is operated:

More from Dana Blankenhorn...

The engineers attached compact microscope lenses to a holder fitted to a cell phone. Using samples of infected blood and sputum, the researchers were able to use the camera phone to capture bright field images of Plasmodium falciparum, the parasite that causes malaria in humans, and sickle-shaped red blood cells. They were also able to take fluorescent images of Mycobacterium tuberculosis, the bacterial culprit that causes TB in humans. Moreover, the researchers showed that the TB bacteria could be automatically counted using image analysis software.

The engineers had previously shown that a portable microscope mounted on a mobile phone could be used for bright field microscopy, which uses simple white light — such as from a bulb or sunlight — to illuminate samples. The latest development adds to the repertoire fluorescent microscopy, in which a special dye emits a specific fluorescent wavelength to tag a target - such as a parasite, bacteria or cell - in the sample.

The researchers used filters to block out background light and to restrict the light source, a simple light-emitting diode (LED), to the 460 nanometer wavelength necessary to excite the green fluorescent dye in the TB-infected blood. Using an off-the-shelf phone with a 3.2 megapixel camera, they were able to achieve a spatial resolution of 1.2 micrometers. In comparison, a human red blood cell is about 7 micrometers in diameter.

The researchers pointed out that while fluorescent microscopes include additional parts, less training is needed to interpret fluorescent images. Instead of sorting out pathogens from normal cells in the images from standard light microscopes, health workers simply need to look for something the right size and shape to light up on the screen.

Article in PLoS ONE: Mobile Phone Based Clinical Microscopy for Global Health Applications...

Press release with video of the microscope in action: UC Berkeley researchers bring fluorescent imaging to mobile phones for low-cost screening in the field...

Side image: Fluorescent image of TB bacteria taken by the CellScope.

Flashback: CellScope for Rural Microscopy On The Go

Here's a TED talk of Kraft presenting the MarrowMiner device:

More from TED: Daniel Kraft invents a better way to harvest bone marrow

Product page: MarrowMiner...